scholarly journals Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy

2007 ◽  
Vol 96 (8) ◽  
pp. 1183-1190 ◽  
Author(s):  
A Sultana ◽  
C Tudur Smith ◽  
D Cunningham ◽  
N Starling ◽  
D Tait ◽  
...  
2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 348-348
Author(s):  
Adnan Nagrial ◽  
Venessa T. Chin ◽  
Chelsie O'Connor ◽  
Katrin Marie Sjoquist ◽  
Lorraine A. Chantrill ◽  
...  

348 Background: The role of combined modality therapy in the management of locally advanced pancreatic cancer (LAPC) is uncertain. Current guidelines recommend combined modality therapy for select patients. We sought to review the evidence for combined modality versus single modality therapy in LAPC. We performed a systematic review and meta-analysis of randomised controlled trials (RCT) comparing chemoradiation versus chemotherapy alone as well as chemoradiation versus radiation alone in patients with LAPC. Methods: We searched MEDLINE, EMBASE and CENTRAL from inception to Oct 2013 for RCTs comparing chemotherapy alone versus chemotherapy plus radiation and radiation alone versus chemotherapy plus radiation. We also searched abstracts of major cancer meetings from 1990 to 2013. The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), response rate and adverse events. Hazard ratios (HR), confidence intervals (CI) and p-values (p) were estimated with a random-effects model due to the heterogeneity of included studies using Revman 5.3. Results: We included 7 eligible trials including 753 patients. Induction chemotherapy was delivered prior to randomisation in one study. Chemoradiation versus chemotherapy (n= 5 studies) did not improve PFS (HR 1.02, 95% CI 0.87 - 1.20, p = 0.80) or OS (HR 0.91, 95% CI 0.64 - 1.31, p = 0.61). However, chemoradiation versus radiation (n=2 studies) improved PFS (HR 0.63, 95% CI 0.41 - 0.96, p = 0.03) and OS (HR 0.65, 95% CI 0.43 – 0.96, p = 0.03). There was significant statistical heterogeneity in the included studies and subsequently wide confidence intervals in the pooled results. This is most likely due to the small participant numbers in each study. Adverse events were more frequent in the chemoradiation arms. Response rates were assessed in only two studies. Conclusions: Chemoradiation is not superior to chemotherapy alone in LAPC, but may be superior to radiation alone. The studies were small with significant heterogeneity. Combined modality therapy results in increased adverse events. Our results do not provide evidence for a universal standard of care, thus more studies of combined modality therapy in LAPC are needed.


2016 ◽  
Vol 23 (13) ◽  
pp. 4352-4360 ◽  
Author(s):  
Steffi J. Rombouts ◽  
Marieke S. Walma ◽  
Jantien A. Vogel ◽  
Lennart B. van Rijssen ◽  
Johanna W. Wilmink ◽  
...  

Pancreatology ◽  
2014 ◽  
Vol 14 (3) ◽  
pp. S43-S44
Author(s):  
Steffi Rombouts ◽  
Samira Fegrachi ◽  
Hjalmar van Santvoort ◽  
Marc Besselink ◽  
Richard van Hillegersberg ◽  
...  

2003 ◽  
Vol 21 (18) ◽  
pp. 3409-3414 ◽  
Author(s):  
Monika K. Krzyzanowska ◽  
Jane C. Weeks ◽  
Craig C. Earle

Purpose: To evaluate the use and effectiveness of cancer-directed therapy in elderly patients with locally advanced pancreatic cancer (LAPC). Methods: We used the linked Surveillance, Epidemiology, and End Results Medicare database to perform a retrospective cohort study in 1,696 patients diagnosed with LAPC between 1991 and 1996. We calculated cancer-directed treatment use rates, then used logistic regression to identify patient and health system factors that were associated with receipt of treatment. Effectiveness of treatment was estimated using Cox proportional hazards models and propensity score methods. Results: In our cohort, 44% of patients received some form of cancer-directed therapy (24% radiation with concurrent chemotherapy, 13% radiation alone, and 7% chemotherapy alone). Older age, lower socioeconomic status, presence of comorbid illness, no care in a teaching hospital, and residence in the western United States were associated with a lower likelihood of receiving treatment (P ≤ .05). Among those treated, younger age and certain geographic locations were the only predictors of receiving combined-modality therapy. The adjusted hazard ratio for death associated with any treatment in the Cox model was 0.53 (P < .0001). Effectiveness estimates obtained using propensity score methods were similar. Conclusion: This analysis supports the effectiveness of cancer-directed treatment in elderly patients with LAPC, but use is low. Receipt of treatment is strongly correlated with non–disease-related factors, especially sociodemographic characteristics, indicating possible disparities in access to care.


Pancreatology ◽  
2016 ◽  
Vol 16 (3) ◽  
pp. S88-S89
Author(s):  
Marieke Walma ◽  
Steffi Rombouts ◽  
Jantien Vogel ◽  
Lennart van Rijssen ◽  
Johanna Wilmink ◽  
...  

2016 ◽  
Vol 103 (8) ◽  
pp. 941-949 ◽  
Author(s):  
S. Klompmaker ◽  
T. de Rooij ◽  
J. J. Korteweg ◽  
S. van Dieren ◽  
K. P. van Lienden ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document